JP2013545759A5 - - Google Patents

Download PDF

Info

Publication number
JP2013545759A5
JP2013545759A5 JP2013540063A JP2013540063A JP2013545759A5 JP 2013545759 A5 JP2013545759 A5 JP 2013545759A5 JP 2013540063 A JP2013540063 A JP 2013540063A JP 2013540063 A JP2013540063 A JP 2013540063A JP 2013545759 A5 JP2013545759 A5 JP 2013545759A5
Authority
JP
Japan
Prior art keywords
cancer
tumor
ldh
ldh5
ldh4
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013540063A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013545759A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/061453 external-priority patent/WO2012068491A1/en
Publication of JP2013545759A publication Critical patent/JP2013545759A/ja
Publication of JP2013545759A5 publication Critical patent/JP2013545759A5/ja
Pending legal-status Critical Current

Links

JP2013540063A 2010-11-18 2011-11-18 低酸素状態に基づくエレスクロモールによる治療に適した被験体の事前選択 Pending JP2013545759A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41510410P 2010-11-18 2010-11-18
US61/415,104 2010-11-18
PCT/US2011/061453 WO2012068491A1 (en) 2010-11-18 2011-11-18 Preselection of subjects for therapeutic treatment with elesclomol based on hypoxic status

Publications (2)

Publication Number Publication Date
JP2013545759A JP2013545759A (ja) 2013-12-26
JP2013545759A5 true JP2013545759A5 (enExample) 2015-01-15

Family

ID=45217701

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013540063A Pending JP2013545759A (ja) 2010-11-18 2011-11-18 低酸素状態に基づくエレスクロモールによる治療に適した被験体の事前選択

Country Status (4)

Country Link
US (2) US20120128580A1 (enExample)
EP (1) EP2640372A1 (enExample)
JP (1) JP2013545759A (enExample)
WO (1) WO2012068491A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130149392A1 (en) * 2011-12-12 2013-06-13 Synta Pharmaceuticals Corp. Method of treating non-small cell lung cancer with bis-(thiohydrazide)amide compounds
WO2020102303A1 (en) * 2018-11-14 2020-05-22 The Broad Institute, Inc. Use of disulfiram and other compounds to treat cancers with loss of chromosome 16q and/or low expression of metallothionein proteins
WO2021162478A1 (ko) * 2020-02-14 2021-08-19 사회복지법인 삼성생명공익재단 게니핀 및 엘레스클로몰을 포함하는 암 예방 또는 치료용 약학적 조성물
CN112618527B (zh) * 2021-01-20 2021-11-09 上海交通大学医学院附属第九人民医院 一种小分子在制备突变型葡萄膜黑色素瘤药物中的应用
WO2023276768A1 (ja) * 2021-06-29 2023-01-05 国立大学法人京都大学 低酸素バイオマーカー及びその利用
CA3235940A1 (en) * 2021-10-21 2023-04-27 Jeffrey A. BACHA Compositions and methods for treatment of hyperproliferative, inflammatory, and immunological diseases, and infections
CN115581775B (zh) * 2022-09-26 2025-09-30 广州医科大学附属第三医院(广州重症孕产妇救治中心、广州柔济医院) 一种用于治疗骨肉瘤的复合纳米药剂及其制备方法
CN118453879B (zh) * 2024-05-23 2025-10-03 大连医科大学附属第二医院 恩杂鲁胺与铜离子载体联合在制备前列腺癌治疗药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4250255A (en) 1977-07-11 1981-02-10 Eastman Kodak Company Assay method for isoenzyme activity
US6242208B1 (en) 1988-07-15 2001-06-05 International Reagents Corporation LDH1 assay
PL1781604T3 (pl) 2004-06-23 2014-01-31 Synta Pharmaceuticals Corp Sole bis(tiohydrazydoamidu) do leczenia nowotworów
EP1731617A1 (de) 2005-06-06 2006-12-13 DSM IP Assets B.V. Rückführung lysierter Biomasse als Nährmedium bei der fermentativen Herstellung von Riboflavin
SE530596C2 (sv) 2006-10-13 2008-07-15 Mathias Karlsson Metod att fastställa syrebrist i blod från skalpen under förlossning
EP2099933A4 (en) 2006-11-21 2010-03-24 Beth Israel Hospital HYPOXIA-ASSOCIATED GENES AND PROTEINS FOR THE TREATMENT AND DIAGNOSIS OF PREGNANCY-RELATED COMPLICATIONS
AU2008338594A1 (en) * 2007-12-14 2009-06-25 Sciclone Pharmaceuticals, Inc. Treatment of melanoma with alpha thymosin peptides in combination with an antineoplastic heat shock apoptosis activator (HSAA)
US8815945B2 (en) * 2010-04-20 2014-08-26 Masazumi Nagai Use of bis [thiohydrazide amide] compounds such as elesclomol for treating cancers

Similar Documents

Publication Publication Date Title
JP2014503499A5 (enExample)
JP2014503500A5 (enExample)
JP2013545759A5 (enExample)
Oudijk et al. SDHA mutations in adult and pediatric wild-type gastrointestinal stromal tumors
Tian et al. Autophagy inhibits oxidative stress and tumor suppressors to exert its dual effect on hepatocarcinogenesis
Tovar et al. Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma
Kutikhin Role of NOD1/CARD4 and NOD2/CARD15 gene polymorphisms in cancer etiology
Schietke et al. Renal tubular HIF-2α expression requires VHL inactivation and causes fibrosis and cysts
Alexander et al. p16 expression is not associated with human papillomavirus in urinary bladder squamous cell carcinoma
Han et al. Discovery of ARD-2051 as a potent and orally efficacious proteolysis targeting chimera (PROTAC) degrader of androgen receptor for the treatment of advanced prostate cancer
Chang et al. Use of PAX8 and GATA3 in diagnosing sarcomatoid renal cell carcinoma and sarcomatoid urothelial carcinoma
Gandhi et al. Urothelial carcinoma: divergent differentiation and morphologic subtypes
Li et al. Expression of Wnt-5a and β-catenin in primary hepatocellular carcinoma
JP2022050493A (ja) 癌を治療する方法における使用のための毛細血管拡張性運動失調症の変異したRad3関連タンパク質キナーゼ(ATR)の阻害剤
Toumpeki et al. The role of ARID1A in endometrial cancer and the molecular pathways associated with pathogenesis and cancer progression
Xu et al. VHL inactivation induces HEF1 and Aurora kinase A
MY156210A (en) Compounds and methods for kinase modulation, and indications therefor
Tian et al. Differential expression of enhancer of zeste homolog 2 (EZH2) protein in small cell and aggressive B-cell non-Hodgkin lymphomas and differential regulation of EZH2 expression by p-ERK1/2 and MYC in aggressive B-cell lymphomas
Wang et al. Semaphorin 4D and hypoxia-inducible factor-1α overexpression is related to prognosis in colorectal carcinoma
WO2017103147A1 (en) Method for assessing the response to pd-1/pdl-1 targeting drugs
Liu et al. Low density lipoprotein receptor class A domain containing 4 (LDLRAD4) promotes tumorigenesis of hepatic cancer cells
Krishnamurthy et al. Targeting the mutant PIK3CA gene by DNA‐alkylating pyrrole‐imidazole polyamide in cervical cancer
Wang et al. Roles of miR-186 and PTTG1 in colorectal neuroendocrine tumors
Halvarsson et al. Loss of mismatch repair protein immunostaining in colorectal adenomas from patients with hereditary nonpolyposis colorectal cancer
CA3075215A1 (en) Hdac inhibitor in combination with immune checkpoint modulator for cancer therapy